In last trading session, Eton Pharmaceuticals Inc (NASDAQ:ETON) saw 0.4 million shares changing hands with its beta currently measuring 1.31. Company’s recent per share price level of $18.93 trading at -$0.77 or -3.91% at ring of the bell on the day assigns it a market valuation of $507.66M. That closing price of ETON’s stock is at a discount of -13.47% from its 52-week high price of $21.48 and is indicating a premium of 83.2% from its 52-week low price of $3.18. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.32 million shares which gives us an average trading volume of 262.50K if we extend that period to 3-months.
For Eton Pharmaceuticals Inc (ETON), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.01 in the current quarter.
Eton Pharmaceuticals Inc (NASDAQ:ETON) trade information
Upright in the red during last session for losing -3.91%, in the last five days ETON remained trading in the green while hitting it’s week-highest on Wednesday, 05/14/25 when the stock touched $18.93 price level, adding 11.87% to its value on the day. Eton Pharmaceuticals Inc’s shares saw a change of 42.12% in year-to-date performance and have moved 12.75% in past 5-day. Eton Pharmaceuticals Inc (NASDAQ:ETON) showed a performance of 34.45% in past 30-days. Number of shares sold short was 0.7 million shares which calculate 2.79 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 13 to the stock, which implies a fall of -45.62% to its current value. Analysts have been projecting 11 as a low price target for the stock while placing it at a high target of 15. It follows that stock’s current price would jump 41.89% in reaching the projected high whereas dropping to the targeted low would mean a gain of 41.89% for stock’s current value.
Eton Pharmaceuticals Inc (ETON) estimates and forecasts
This year revenue growth is estimated to rise 97.90% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 16.31M for the same. And 3 analysts are in estimates of company making revenue of 19.07M in the next quarter. Company posted 9.07M and 10.32M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 32.22% during past 5 years.
Eton Pharmaceuticals Inc (NASDAQ:ETON)’s Major holders
Insiders are in possession of 5.17% of company’s total shares while institution are holding 52.42 percent of that, with stock having share float percentage of 55.28%. Investors also watch the number of corporate investors in a company very closely, which is 52.42% institutions for Eton Pharmaceuticals Inc that are currently holding shares of the company. OPALEYE MANAGEMENT INC. is the top institutional holder at ETON for having 2.4 million shares of worth $7.88 million. And as of 2024-06-30, it was holding 9.2963 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 1.03 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.989 of outstanding shares, having a total worth of $3.38 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 681.72 shares of worth $12.9 million or 2.54% of the total outstanding shares. The later fund manager was in possession of 343.6 shares on Dec 31, 2024 , making its stake of worth around $6.5 million in the company or a holder of 1.28% of company’s stock.
